Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Chemoradiotherapy for Esophageal Small Cell Carcinoma
NCT06478264Phase 2Not yet recruiting
- Sponsor
- Zhangzhou Municipal Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell carcinoma of the esophagus (SCEC), sponsored by Zhangzhou Municipal Hospital. Primary endpoint: Objective Response Rate at 1 year. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell carcinoma of the esophagus (SCEC)
Beyond the preview
Go deeper on NCT06478264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478264.